Samsung Biologics has appointed Eun Young Yang as vice president of business development for the company’s expanded CDO (contract development organization) business.

Ms. Yang is a registered pharmacist both in the U.S. and in South Korea with more than 20 years of experience in marketing, sales, and business development at global pharmaceutical companies including Roche and Eli Lilly.   

“Eun is one of the key founding members of Samsung Biologics’ CDO department,” said Tae Han Kim, CEO of Samsung Biologics. “She has played a significant role in growing our CDO business, bringing in 50 development projects from local & global clients to date, and will spearhead our strategy and business development focus to meet the evolving global needs of our clients.”

Samsung Biologics offers manufacturing capacity of 364,000L at a single location, and expanded its portfolio with contract development services as part of their business growth strategy. Samsung Biologics CDO offers cell line development to IND filing. The company also plans for geographical expansion by opening its first global CDO R&D center in San Francisco this year.